The defendable thinking behind a foot-at-risk platform. Sourced.
Every number sourced to JAMA 2023 / NEJM: the DFU burden (18.6M/yr, $9–13B, >70% mortality after amputation) and the recurrence engine (65% within 5 years) that makes the longitudinal record the moat.
The epidemiology: trauma, neuropathy, PAD, RA — why the at-risk foot is a mechanism, not a diagnosis.
Athletes as a wedge; and why the owned, portable, longitudinal record — not the model — is the product.
The accuracy roadmap: capture quality → clinician ground truth → foot LoRA → SigLIP hybrid, measured against a golden set.
Why the lab domain that feeds the ecosystem, with the defendable data behind it.